Protocol Ledger

NCT06010303 · Phase II · COMPLETED

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Interventional Phase II clinical trial protocol NCT06010303 sponsored by BeiGene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-08 Enrollment: 118 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06010303
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)118 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06010303
Protocol FieldVerified Registry Value
NCT IdentifierNCT06010303
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment118 participants (ACTUAL)
Registered Start Date2023-11-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI